The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

-The Economic Times The government is reviewing the norms for keeping buffer stocks of wheat and rice required at a particular time of the year to feed the public distribution system and welfare schemes. The demand for wheat and rice distributed through welfare schemes is expected to rise with the implementation of the food security law. "The government is looking at the issue and we are discussing it with different departments," KV Thomas,...

-The Economic Times The recent patent rulings in India may get frequently challenged in international courts if the government yields to the European Union's demand of including matters related to intellectual property in the investors-state dispute mechanism in their proposed trade pact, health activist groups have warned. An investor-state dispute resolution mechanism typically allows foreign investors to sue countries for compensation if national laws, policies, court rulings of the country infringe upon...

-Outlook India has long been the sleeping giant of global agriculture. But its misguided policies while boosting short-term output, yet may transform India into a food importer After decades on the sidelines of international agricultural trade, India was poised last year to become a major food supplier, overtaking traditional exporters of food grain and meat. This could prove to be flash in the pan. The sudden rise and fall of India...

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...